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Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania; 2Howard Hughes Medical Institute, Philadelphia, Pennsylvania; 3University of
Pennsylvania School of Medicine, Philadelphia, Pennsylvania; 4Uniformed Services University of Health Sciences (USUHS), Bethesda, Maryland;
5
EpiVax, Inc., Providence, Rhode Island; 6Institute for Immunology and Informatics, University of Rhode Island, Providence, RI
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Immune responses directed against viral capsid proteins constitute a main safety concern in the use of
adeno-associated virus (AAV) as gene transfer vectors in
humans. Pharmacological immunosuppression has been
proposed as a solution to the problem; however, the
approach suffers from several potential limitations. Using
MHC class II epitopes initially identified within human
IgG, named Tregitopes, we showed that it is possible to
modulate CD8+ T cell responses to several viral antigens
in vitro. We showed that incubation of peripheral blood
mononuclear cells with these epitopes triggers proliferation of CD4+CD25+FoxP3+ T cells that suppress killing of
target cells loaded with MHC class I antigens in an antigen-specific fashion, through a mechanism that seems
to require cell-to-cell contact. Expression of a construct
encoding for the AAV capsid structural protein fused to
Tregitopes resulted in reduction of CD8+ T cell reactivity
against the AAV capsid following immunization with an
adenoviral vector expressing capsid. This was accompanied by an increase in frequency of CD4+CD25+FoxP3+
T cells in spleens and lower levels of inflammatory infiltrates in injected tissues. This proof-of-concept study
demonstrates modulation of CD8+ T cell reactivity to an
antigen using regulatory T cell epitopes is possible.
Received 22 December 2012; accepted 8 July 2013; advance online
publication 13 August 2013. doi:10.1038/mt.2013.166

INTRODUCTION

Clinical gene therapy has made considerable progress over the
past several years. Despite the recently reported successful clinical
trial results using adeno-associated virus (AAV) vectors,1 the most
commonly used vector for in vivo gene transfer, host immune
responses directed against the AAV capsid remain a major obstacle to achieving long-term correction of disease phenotype.2 A
capsid-specific CD8+ T cell response was initially identified as the
cause of short-lived transgene expression in the first clinical trial
in which an AAV2 vector expressing coagulation factor IX (FIX)
was introduced into the liver of severe hemophilia B subjects.3 In
this trial, upon AAV gene transfer to liver, two subjects developed

transient elevation of liver enzymes consequent to what appeared
to be the immune rejection of transduced hepatocytes mediated
by capsid-specific CD8+ T cells.4 A similar set of observations
was recently made in the context of a clinical trial of hepatic gene
transfer for FIX with an AAV8 vector.5 Results from these studies
suggest that AAV vector administration in humans results in activation of capsid-specific CD8+ T cells in a vector dose-dependent
fashion, with loss of transgene expression and increase in liver
enzymes occurring above a certain vector dose threshold.
AAV vectors are nonreplicating recombinant viruses carrying
a single-stranded DNA genome devoid of viral coding sequence;
this genome is contained in a protein capsid comprising three
structural proteins, VP1, VP2, and VP3.6 Upon infection, the viral
vector capsid is present within a target cell for a defined period of
time and is degraded through the proteasome pathway,7–9 leading
to MHC class I (MHC I) presentation of AAV capsid epitopes,
which ultimately flags transduced cells for destruction by capsidspecific CD8+ T cells.7,8 Humans are naturally exposed to AAV,
and develop both humoral and cellular immunity to the virus
early in life.10–12 Whereas anti-AAV antibodies can completely
block vector transduction, particularly when the vector is delivered through the bloodstream,3,13 loss of therapeutic transgene
expression is believed to be related to the concomitant presentation of capsid antigen and activation of capsid-specific CD8+ T
cells, resulting in clearance of AAV vector-transduced cells.3–5,14
Immune suppression can be used to induce tolerance in a variety of settings.15 In the most recent AAV8-FIX trial, capsid T cell
responses were controlled with the administration of a short course
of high-dose oral prednisolone;5 however the safety and efficacy of
this intervention at higher vector doses, such as the doses required
to achieve therapeutic efficacy in diseases like hemophilia A or
muscular dystrophy, remains unknown. Additional concerns over
the risks associated with the use of immunosuppression, as well
as the fact that administration of steroids in certain subsets of
patients is not recommended, have prompted the exploration of
alternative strategies for the modulation of capsid T cell responses.
Regulatory T cell (Treg)-mediated immunomodulation has
been explored as a therapeutic strategy in transplantation16 and
autoimmunity.17 Tregs play a central role in the maintenance of
peripheral tolerance and the control of immune responses. Tregs
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have been shown to downregulate effector responses via a variety
of mechanisms, which include the consumption of IL-2, secretion
of suppressor cytokines, interference of antigen-presenting cellmediated activation of effector T cells (Teff), the cytolysis of Teff,
or direct cell-cell interaction mediated by surface receptor(s) at
the surface of Treg and Teff.18 Whereas in some cases, the interaction between Treg and Teff results in the death or cell cycle arrest
of Teff, in some cases, it results in anergy, a state of unresponsiveness that can be reversed by removing Tregs.19
De Groot and colleagues first described the use of MHC class
II (MHC II) epitopes located in the Fc region of IgG to modulate immunity.20 Coadministration of these regulatory T cell epitopes (Tregitopes) with immunogenic antigen reduces immune
response in vitro and in vivo.21–24 In particular, Tregitopes have
been shown to downregulate CD4+ T cell responses in the setting
of common immunogens20 and in models of autoimmune diseases such as experimental colitis.22 The postulated mechanism
of action of Tregitopes involves the presentation of the peptides
onto MHC II by antigen-presenting cells, resulting in early secretion of IL-10 and promoting proliferation of Tregs. However, no
study has been published so far on the effect of Tregitopes on
CD8+ T cell responses; similarly, insights on the mechanism(s)
of suppression of Teff responses by Tregitope-induced Tregs are
still lacking.
Here, we assessed the potential of these peptides as modulators of capsid-specific CD8+ T cell immunity and provide new
insight as to their mechanism of action. In vitro experiments using
human cells show that co-incubation of Tregitopes with AAVderived epitopes completely blunts capsid-specific CD8+ T cell
responses and results in robust expansion of CD4+CD25+FoxP3+
T cells. Additional experiments suggest that Tregitopes expand
antigen-specific Tregs, and that these peptides can be used to
modulate Th1 responses directed against several antigens in the
context of multiple MHC I alleles. Finally, expression of Tregitopes
in vivo also decreases CD8+ T cell responses directed against the
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To test the ability of IgG-derived MHC II epitopes (Tregitopes)
to modulate AAV capsid-directed T cell responses, we used an in
vitro experimental model previously described (Supplementary
Figure S1).7,8 Briefly, human peripheral blood mononuclear
cells (PBMCs) were restimulated in vitro with AAV capsidderived MHC I epitopes and Tregitopes or control peptides in
the presence of IL-2 before using them as effectors (Teff) in a
CTL assay against HLA-matched peptide-loaded or AAVtransduced targets. Restimulation of Teff in the presence of
Tregitope 167 (hTreg167), but not in the presence of three different scrambled versions of the same peptide, resulted in an
almost complete loss of CTL activity against HLA-matched
targets loaded with the HLA-B*0702 epitope VPQYGYLTL
from AAV (Figure 1a). In this in vitro experimental system,
we tested PBMCs from different donors with various MHC II
haplotypes, showing a slight but not statistically significant (P =
0.1873, linear regression), correlation between the affinity of
Tregitopes for one subject’s MHC II alleles (iTEM score)25
and the inhibition of Teff responses (Supplementary Figure
S2). Then, we tested whether Tregitope modulation of CTL
responses was also effective in the context of MHC I antigens
naturally processed and presented via the proteasome pathway by transducing HLA-B*0702 targets with AAV vectors at
increasing multiplicity of infections, showing effective inhibition of CTL activity (Figure 1b). Restimulation of PBMCs in the
presence of hTreg167 resulted in a profound downregulation of
markers of T cell activation and effector functions (Figure 1c).
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Figure 1 IgG-derived MHC class II epitopes (Tregitopes) mediate suppression of T cell responses in vitro. (a) CTL assay in which target cells
were loaded with the AAV-derived MHC I epitope VPQYGYLTL (HLA-B*0702-restricted) at increasing concentrations and then incubated with HLAmatched Teff cells. Effectors were derived from HLA-B*0702 PBMC expanded in vitro against the same MHC I epitope alone (AAV, dashed line), or with
hTreg167 (AAV+hTreg167, black line), or with three different scrambled versions of hTreg167 (Scramble 1, Scramble 2, and Scramble 3, grey lines).
Teff:target ratio 10:1. Results are expressed as % cytotoxicity compared with a maximum cytotoxicity (cells treated with 10% SDS) after background
subtraction. (b) CTL assay in which target cells were transduced with an AAV vector at increasing multiplicity of infections (MOIs) and then incubated
with HLA-matched Teff cells restimulated with the AAV capsid MHC I peptide VPQYGYLTL alone (dashed line), or together with hTreg167 (black line).
MOI, multiplicity of infection. Teff:target ratio 10:1. (c) Flow cytometry analysis of CD8+ T cell responses to the AAV MHC I epitope VPQYGYLTL.
PBMC were restimulated in vitro in the presence of the AAV MHC I peptide VPQYGYLTL alone (AAV) or with hTreg167 (AAV+hTreg167) and then
washed and incubated with the VPQYGYLTL peptide and stained for markers of T cell effector functions. Results are expressed as fold increase over
non-restimulated PBMC incubated with the MHC I peptide VPQYGYLTL. For the analysis of flow cytometry data, after live/dead exclusion, cells were
gated on lymphocytes, CD3+ T cells, and CD8+ T cells were then analyzed for IFN-γ, IL-2, TNF-α. SEB, Streptococcal enterotoxin B. Experiments
shown were repeated at least twice. Error bars represent SEM. MFI, mean fluorescence intensity.
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Figure 2 Tregitopes can modulate CTL responses directed against several antigens and in the context of different HLA alleles. (a–d) Teff
specific for Epstein-Barr virus (EBV), cytomegalovirus (CMV), hepatitis C virus (HCV), or influenza virus (Flu) were obtained following the protocol
outlined in Figure S1. All MHC I epitopes were HLA-B*0702-restricted. Teff were used in the CTL assay at a Teff:target ratio of 1:10. Targets were
peptide loaded with increasing concentrations of the relevant peptide. Results are expressed as % cytotoxicity compared to a max cytotoxicity (cells
treated with 10% SDS) after background subtraction. Dashed line, Teff expanded from PBMC restimulated in vitro with indicated viral peptide only;
Black line, Teff expanded in vitro with indicated viral peptide and hTreg167. (e) CTL assay in which Tregitope efficacy was tested against the AAV
HLA-A*0101 restricted MHC I epitope SADNNNSEY. HLA-matched Teff were used in the CTL assay at a Teff:target ratio of 1:10. Targets were peptide
loaded with increasing concentrations of the relevant peptide. Results are expressed as % cytotoxicity compared to a max cytotoxicity (cells treated
with 10% SDS) after background subtraction. Dashed line, effectors obtained by restimulating PBMC in vitro with the SADNNNSEY epitope only;
Black line, restimulation of PBMC was performed with the SADNNNSEY epitope from AAV and hTreg167. (f) CTL assay in which targets were loaded
with the HLA-B*0702 epitope VPQYGYLTL from AAV. Teff were either obtained restimulating PBMC with the same AAV peptide only (AAV), or with
the AAV peptide and Tregitope 167 (AAV+hTreg167), or with the AAV peptide and Tregitope 289 (AAV+hTreg289). Teff were used in the CTL assay at
a Teff:target ratio of 1:10. Targets were peptide loaded with increasing concentrations of the relevant peptide. Results are expressed as % cytotoxicity
compared to a max cytotoxicity (cells treated with 10% SDS) after background subtraction. Experiments shown were repeated at least twice. Error
bars represent SEM.

Inhibition of Teff responses upon restimulation in the presence
of hTreg167 was achieved with MHC I peptide epitopes derived
from several additional HLA-B*0702-restricted viral antigens
(Figure 2a–2d) but also with MHC I epitopes with different
HLA restrictions (Figure 2e) and with hTreg289 (Figure 2f), a
peptide with a different MHC II binding profile that was also
derived from the Fc portion of human IgG.20 Suppression of CTL
responses with hTreg289 was less effective than with hTreg167,
which reflects the HLA haplotype of the donor (DRB1*0701 and
DRB1*1501) and the fact that hTreg289 is predicted to bind only
to DRB1*0701, while hTreg167 binds to both alleles.20 PBMCs
labeled with CFSE prior to in vitro restimulation with AAV capsid epitopes showed that in the presence or absence of hTreg167,
both CD4+ and CD8+ T cells proliferate (Supplementary
Figure S3); however, CD8+ T cells restimulated in the presence
of Tregitopes exhibited lower levels of expression of the activation marker CD25 (Figure 3a,b), while there was an increase
in the frequency of CD25+CD4+ T cells (vide infra). ELISA
assay on conditioned media from PBMC cultured in the presence of Tregitopes showed the presence of lower levels of IL-2
(Supplementary Figure S4, P = 0.0005, two-way ANOVA) and
increased levels of IL-10 (Supplementary Figure S4, P = 0.0298,
two-way ANOVA). No additional cytokine or chemokine analytes were changed, when measured by multiplex analysis of the
Molecular Therapy vol. 21 no. 9 sep. 2013

conditioned media collected at multiple time points during the
PBMC restimulation (not shown).
These results indicate that Tregitopes added in restimulation cultures efficiently modulate CD8+ T cell responses directed
against a variety of HLA class I-restricted viral epitopes in vitro.

Restimulation of PBMCs in vitro with Tregitopes
expands suppressive CD4+CD25+ T cells
We then looked at the expansion of CD4+CD25+ T cells in
restimulation cultures containing AAV MHC I peptide epitope only or in cultures containing Tregitopes. A population
of CD4+CD25+ T cells was preferentially expanded when
Tregitopes were added to the cultures (Figure 3a,b). These cells
expressed FoxP3 (Figure 3c). Additional immunophenotyping
of these CD4+CD25+ T cells showed that these cells were mostly
CD127neg and expressed CTLA4 (not shown). Using negative bead
selection, we isolated untouched CD4+ T cells (Tsupp) and used
them in a suppression assay; these cells showed dose-dependent
suppressor activity, with a dramatic reduction of CTL activity at a
Tsupp:Teff cell ratio of 1:1 (Figure 3d). Magnetic bead depletion
of the CD25+ cell fraction from PBMCs prior to in vitro restimulation resulted in the loss of modulatory activity of Tregitopes
(Figure 3e), suggesting that Tregitopes exert their functions via a
pool of existing T cells present in peripheral blood.
1729
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Figure 3 In vitro restimulation of PBMC with Tregitopes results in the expansion of a population of suppressive CD4+CD25+ T cells. Flow
cytometry plots of PBMC restimulated in vitro with the AAV MHC I epitope VPQYGYLTL alone (AAV) (a) or with Tregitope 167 (AAV+hTreg167)
(b). Cells were gated on lymphocytes after live/dead exclusion, CD3+ T cells, and CD4+CD8- and CD4-CD8+ T cells were analyzed for CD25+.
(c) Histogram plot showing FoxP3 expression on CD4+CD25+ T cells restimulated with AAV-only from (a) or AAV+hTreg167 from (b); the isotype
control is shown in red. Mean fluorescent intensity (MFI) is indicated in the figure legend. (d) Suppression experiments in which CD4+ T cells (Tsupp)
negatively isolated from PBMC restimulated in vitro with AAV+hTreg167 (blue line) or with AAV only (green line) were mixed at defined ratios with
CD8+ Teff negatively isolated from PBMC restimulated in vitro with the AAV only. (e) CTL assay in which Teff were derived from PBMC restimulated
in vitro with AAV alone (AAV) or with Tregitope 167 (AAV+hTreg167). Alternatively, PBMC were depleted of CD25+ T cells prior to AAV+hTreg167
restimulation (AAV+hTreg167 [CD25neg]). Teff:target ratio 10:1. Results are expressed as % cytotoxicity compared to a max cytotoxicity (cells treated
with 10% SDS) after background subtraction. Experiments shown were repeated at least twice. Error bars represent SEM.

These results suggest that restimulation of PBMCs in
vitro in the presence of Tregitopes expands a pool of natural
CD4+CD25+FoxP3+ T cells with suppressive functions.

Tregitope-mediated modulation of CTL responses
in vitro is contact dependent and associated with
anergy of effector T cells
To investigate the mechanism(s) of action of Tregitopes in vitro,
we carried out two experiments. In the first experiment, we tested
whether cell-to-cell contact was a requirement for CTL inhibition. For this purpose, PBMCs were depleted of CD4+ or CD8+
T cells, and the CD4+CD8neg and the CD4negCD8+ fractions were

separated into the two different compartments of a transwell system before restimulation in vitro (Figure 4a). When unfractionated PBMCs were cultured in both chambers of the transwell,
AAV restimulation led to efficient killing of AAV peptide-loaded
targets, whereas AAV+hTreg167 resulted in the inhibition of
CTL activity as expected (Figure 4a). When CD4+CD8neg and
CD4negCD8+ fractions of PBMCs were cultured in different chambers of the transwell, killing of target was efficient whether or not
1730

Tregitope was present for the restimulation. Suppression of CTL
killing was only observed when Teff were restimulated with both
AAV and hTreg167 (Figure 4a) and located in the same chamber, suggesting that contact between CD4+ and CD8+ T cells is
needed to achieve suppression of CTL responses in vitro.
We then restimulated PBMCs in the presence of Tregitopes,
AAV MHC I peptide, and IL-2 (10 ng/ml) for 14 days (two
rounds of restimulation) and then depleted CD4+ T cells.
Following depletion, we either used the CD4negCD8+ T cell fraction in a CTL assay or incubated the cells with IL-2 (10 ng/ml)
overnight before using them as source of effectors in a CTL assay.
Immediately after removal of CD4+ T cells, CD4negCD8+ T cells
were unable to kill the AAV peptide-loaded target (Figure 4b,
CD4neg); however, a 24-hour incubation with IL-2 resulted in restoration of CTL activity to levels undistinguishable from those
achieved with PBMCs restimulated with AAV MHC I epitopes
only (Figure 4b, CD4neg + IL-2), suggesting that CD8+ T cells
expanded in the presence of Tregitopes become anergic, possibly due to lack of costimulatory signals, and that IL-2 can restore
their killing capacity.
www.moleculartherapy.org vol. 21 no. 9 sep. 2013

© The American Society of Gene & Cell Therapy

% Cytotoxicity

a

Modulation of CD8+ T cell responses to AAV vectors

Permeable
membrane

60
50

Upper chamber

40

Lower chamber

30

ID

20
10

Lower
chamber

Upper
chamber

Restimulation
conditions

PBMC

PBMC

AAV

PBMC

PBMC

AAV + hTreg167

CD8+

+
neg
CD4 CD8

AAV

CD4negCD8+

CD4+CD8neg

AAV + hTreg167

neg

CD4

0
0

5

10

15

20

25

µg/ml AAV peptide

b

60
AAV
AAV + hTreg167 (CD4neg + IL-2)

% Cytotoxicity

50
40
30
20

AAV + hTreg167 (CD4neg)
AAV + hTreg167

10
0
0

100

200

300

AAV MOI (×1000)
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[CD4neg + IL-2], gray line triangles). Teff:target ratio 10:1. Results are expressed as % cytotoxicity compared to a max cytotoxicity (cells treated with
10% SDS) after background subtraction. Experiments shown were repeated at least twice. Error bars represent SEM.

Modulation of CTL responses in vitro is antigen
specific
To test antigen specificity of modulation of CTL responses by
Tregitopes, we performed the following experiment: PBMCs were
restimulated in vitro in the presence of MHC I epitopes derived
from AAV or EBV. Parallel cultures were established from the
same PBMC donor in which cells were restimulated with the same
AAV or EBV MHC I epitopes in the presence of hTreg167. At the
end of the restimulation (14 days), CD4+ T cells (AAV-hTreg167
CD4+ or EBV-hTreg167 CD4+, respectively) were isolated by negative magnetic bead selection, and untouched cells were mixed
with AAV or EBV Teff at a 1:1 ratio. As outlined in Figure 5a,
AAV-hTreg167 CD4+ efficiently suppressed AAV Teff, whereas
EBV-hTreg167 CD4+ did not. Further confirming antigen specificity, we found that AAV-hTreg167 CD4+ did not suppress EBV
Teff, while EBV-hTreg167 CD4+ did (Figure 5b). These results
suggest that the in vitro inhibition of Teff responses mediated by
Tregitopes is antigen specific.
We further investigated the antigen specificity of Tregitopemediated modulation by restimulating PBMCs with the HLAB*0702-restricted AAV epitope VPQYGYLTL and hTreg167.
From these cultures, CD4+ T cells isolated by negative selection
were incubated with increasing amounts of soluble human T cell
Molecular Therapy vol. 21 no. 9 sep. 2013

receptor (TCR) monomers specific for the HLA-B*0702 peptide
VPQYGYLTL8 to block access to MHC I:VPQYGYLTL complexes at the surface of the CD4+ T cells. After 1 hour at room
temperature, cells were washed twice, mixed at a 1:1 ratio with
AAV only-restimulated Teff, and used in a CTL assay against target cells loaded with the same VPQYGYLTL peptide. Incubation
of Tregitope-expanded CD4+ T cells with the soluble TCR monomers resulted in dose-dependent elimination of their suppressor activity (Figure 5c). As a control, Teff derived from PBMCs
restimulated with AAV peptide and no hTreg167 were used,
resulting in efficient killing of targets (Figure 5c, AAV only). As
a second control, Teff restimulated with AAV peptide only were
mixed 1:1 with CD4+ T cells isolated from PBMCs restimulated
with hTreg167 and no AAV peptide; efficient lysis of targets was
also observed in this case, indicating that Tregitopes alone without MHC I epitopes do not modulate CD8+ T cell responses.
Finally, a third control in the experiment consisted of the direct
addition of TCR monomers to the CTL assay in which AAV-only
effectors were used. As previously described,8 this resulted in the
inhibition of killing of target cells due to the blockage of MHC
I by the soluble TCR monomers. These results suggest that the
antigen-specific suppressive activity of Tregitope-expanded suppressor cells is mediated by the presence of antigen-specific MHC
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Figure 5 Antigen-specificity of Tregitopes-induced suppression of CTL responses is mediated by MHC I. (a) CTL assay in which target cells were
loaded with the MHC I epitope VPQYGYLTL from AAV and incubated with HLA-matched AAV-specific Teff alone (AAV, dashed line), or Teff mixed
at a 1:1 ratio with negatively-selected CD4+ T cells from AAV+hTreg167 restimulated PBMC (AAV+[AAV-hTreg167 CD4+], black line), or Teff mixed
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with AAV MHC I epitope only, used as positive control (AAV only). White bar: PBMC restimulated with AAV MHC I only mixed 1:1 with CD4+ T cells
derived from cell restimulated with hTreg167 only, without AAV (hTreg167 only). AAV+AAV-TCR control, CTL in which AAV-only Teff were used the
CTL assay in the presence of 20 µg/ml of AAV-TCR. Shown is the % cytotoxicity. Error bars represent the standard error of the mean of quadruplicate
testing. Comparison of results with the AAV-only condition gave the following p values (unpaired, two-tailed t test): AAV-TCR 0 µg/ml P = 0.00262, 1
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I peptide complexes which may be located on the surface of the
Tregitope-specific Treg cells.

In vivo expression of Tregitopes using AAV vectors
downregulates T cell responses directed against the
AAV capsid
To test efficacy of modulation of T cell responses directed against
the AAV capsid in vivo, we used a previously described model of
adenovirus (Ad) vector-mediated immunization against AAV2,
which is known to result in generation of a strong CD8+ T cell
response directed against the capsid antigen.26
To deliver Tregitopes in vivo, we coexpressed Tregitopes (or a
Scramble control) and the AAV2 capsid protein VP1 separated by
a PACE/Furin cleavage signal27 under the transcriptional control
of a CMV promoter (Figure 6a). These were packaged into AAV1
vectors and given intramuscularly to C57BL/6 mice at a dose of
2 × 1011 vector genomes (vg)/mouse. Six weeks following vector
delivery, mice were challenged (intramuscularly) with 1 × 1011
viral particles of an Ad-AAV2 vector, and animals were sacrificed 9 days later (Figure 6b). Analysis of CD8+ T cell responses
in splenocytes showed a significant downregulation (P = 0.0428,
1732

two-tailed unpaired t-test) of IFN-γ responses directed to the
AAV capsid in animals receiving the AAV-Tregitope vector as
compared with the controls (Figure 6c,d).
An increase in frequency of CD4+CD25+FoxP3+ T cells was
detected in spleens of AAV-Tregitope-injected animals (Figure
6e, P = 0.0256, two-tailed unpaired t-test), whereas a decrease
in muscle CD4+ and CD8+ T cell infiltrates was observed
(Supplementary Figure S5a; cells from five animals per group
were pooled for the analysis). Finally, after Ad-AAV2 immunization, anti-AAV IgG levels were significantly decreased (P =
0.0031, two-tailed, unpaired t-test) in AAV-Tregitope-injected
animals (Supplementary Figure S5b). RT Q-PCR confirmed
transgene expression in muscle following vector delivery in mice
receiving both the AAV-Tregitope and the AAV scramble vectors
(Supplementary Figure S6a); similarly, vector genomes were
detectable in both groups (Supplementary Figure S6b). Despite
the presence of infiltrates, no loss of vector-transduced fibers was
noted, a phenomenon previously associated with the apoptosis of
reactive T cells.28
Although the Tregitope-mediated modulation of T cell
responses in vivo was only partial, these results suggest that the
www.moleculartherapy.org vol. 21 no. 9 sep. 2013
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Figure 6 Expression of Tregitopes in vivo results in modulation of capsid-specific IFN-γ responses. (a) Diagram of the transgene expression cassette used to co-express AAV capsid antigen (AAV2VP1) and Tregitope or Scramble peptides. ITR, inverted terminal repeats; CMV, cytomegalovirus
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proposed approach may be valuable in the modulation of capsid T
cell immunity in vivo and that further studies, in which the dosing
of Tregitopes is calibrated to the antigenic stimulus, may effectively modulate anti-AAV immune responses.

DISCUSSION

Immune responses directed against the AAV capsid constitute an
important obstacle to safe and effective gene transfer in humans.2
Whereas in some cases, pharmacological immunosuppression has
proven efficacious in modulating these responses,5 the potential
limitations of the approach prompted us to explore a more physiological strategy to achieve the goal of sustained gene transfer following in vivo gene delivery with AAV vectors.
Over the past several years, Treg-mediated modulation of
immune responses has been explored in several models of autoimmunity, transplant medicine, and gene transfer.29,30 Peptide-mediated
expansion of Tregs in vivo showed some degree of efficacy in preclinical31 and clinical32 models of autoimmune diseases like lupus.
The work presented here was initiated based on the observation that in vivo administration of IVIg results in modulation of
Molecular Therapy vol. 21 no. 9 sep. 2013

immune responses and is associated with the expansion of regulatory T cells (Tregs),33 and that MHC II epitopes found in IgG
(Tregitopes) have immunomodulatory properties.20,24
Here, we provide direct evidence that Tregitopes can act as
potent modulators of CD8+ T cell responses against an antigen
in vitro, and that expression of Tregitopes in vivo is effective in
reducing T cell activation in response to adenoviral challenge.
We took advantage of an in vitro model of CD8+ T cell
immunity directed against the AAV capsid,4,8 which overcomes
the limitations of animal models34–37 and offers the advantage of
working with effector and target cells that are of human origin
and for which reagents specific to monitor AAV capsid antigen
presentation and immunogenicity are well defined.4,7,8 Our data
with this in vitro system indicate that Tregitopes are highly effective in modulating MHC I-driven T cell responses via the activation of a pool of pre-existing CD4+CD25+ T cells, as suggested
by the following observations: (i) depletion of CD25+ T cells
prior to Tregitope restimulation completely ablates the immunomodulatory effect of Tregitopes. This result is consistent with
the studies that show expansion of Tregs in the thymus following
1733
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Tregitope administration in vivo;22 (ii) in vitro studies also show
that CD8+ Teff cells contacted by Tregitope-expanded suppressor
cells lose their effector function and become anergic, as shown
in suppression experiments in which negatively-selected purified CD4+ (Tsupp) and CD8+ (Teff) cells were mixed together,
resulting in dose-dependent decrease in cytotoxicity; (iii) removal
of CD4+ T cells and incubation of Teff with IL-2 restored cytotoxicity. This is suggestive of a model in which Tregitope-specific
CD4+CD25hiFoxP3+ suppressor cells are expanded in the presence of Tregitopes, and inhibit CD8-mediated CTL activity by
directly contacting the antigen-specific CD8+ Teff via MHC I and
by interfering with IL-2-mediated signaling, even in the presence
of IL-2-supplemented restimulation medium. Secretion of immunomodulatory cytokines does not seem to be the main mechanism of modulation of CD8+ T cell activation and function,
although higher levels of IL-10 are found in cell cultures containing Tregitopes, whereas MHC I-TCR interaction seems to mediate
antigen specificity of CD4+CD25+FoxP3+ T cells expanded with
Tregitopes, at least in vitro. The interaction between suppressor
and effector T cells results in anergy of Teff cells, which is reversible when additional IL-2 is provided.
The antigen specificity of immunomodulation mediated by
Tregitopes is a desirable feature of the approach presented here,
as suppression of immune responses to pathogens would otherwise constitute an important side effect of this strategy, and is a
clear advantage over global suppression of immune responses
with pharmacological agents. Future studies will help assess the
robustness of antigen specificity and the requirement for cell-tocell contact in vivo.
Antigen-specific tolerance via MHC I-TCR interaction has
been described before in the context of veto cells.38 Since the initial
description, several studies identified cells with antigen-specific
MHC-restricted veto properties, including T lymphocytes, NK T
cells, and dendritic cells. In the veto model, TCR-mediated recognition of the antigen presented in the context of MHC I by the
veto cell results in cell death of the effector T cell.39 Furthermore,
antigen presentation by veto cells has been shown to promote B
cell tolerance.40 Both the in vitro and in vivo results presented here
suggest that the veto cell model could be a potential mechanism
of tolerance induction with Tregitopes; however, it should also be
noted that MHC I presentation of antigen by CD4+ T cells in our
model does not result in deletion of reactive CD8+ T cells. Rather,
CD4+CD25+FoxP3+ T cells expanded with Tregitopes appear to
act via deprivation of activation signals.41
For our in vivo experiments, we used a model of adenoviral vector-mediated immunization to the AAV capsid antigen.26
This vaccination model was used to overcome the limitations of
several animal models proposed to mimic capsid T cell immune
responses observed in humans34,35,37 and provide a stringent test to
our strategy. We chose to target the muscle because expression of
transgenes in this tissue is typically immunogenic42 and to colocalize the Tregitope expression and the proinflammatory signal
deriving from the adenoviral vector. Expression of Tregitopes
with AAV vectors allowed us to overcome the potential limitations of delivery of peptides in vivo.
The lower efficacy of effector response suppression with
Tregitopes in vivo compared with in vitro may be the result of the
1734
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stringency of the model. Additional factors that may account for
the lower efficacy of Tregitope in vivo could include suboptimal
levels of IL-2,43 or relatively low levels of expression of Tregitopes.
Despite these potential limitations, our data show that it is
possible to use Tregitopes in vivo to modulate immune responses
to an antigen, and the delivery of these peptides with AAV vectors
could represent a tool with a wide range of applications.
Future developments will include the use of AAV serotypes
with high efficiency of transduction in vivo,44 the expression of
multiple Tregitopes in a single vector, the co-administration
of IL-2 at the time of Tregitope expression, or the expression of
Tregitopes in liver, which per se has tolerogenic properties.45 As
AAV vectors are nonreplicating, recombinant viruses, the window
of time in which the capsid antigen is present and immunologically detectable is limited. Direct engineering of the AAV capsid46
to carry Tregitopes at the N-terminus of the capsid protein VP2, as
opposed to expressing them, could be a viable strategy to limit the
duration of the protolerogenic signal deriving from Tregitopes.
Finally, the recent development of a mouse model of CD8+ T cell
immune responses following liver gene transfer,47 in which loss of
transgene expression and increase in liver enzymes is observed
like in humans, represents an important asset to the development
of ad hoc tolerization protocols with Tregitopes.
In the future clinical translation of the approach presented
here, one potential limitation to the use of Tregitopes is the fact
that efficacy of suppression with these peptides is dependent on
the HLA class II haplotype of the subject. Low affinity of Tregitope
peptides for a subject’s MHC II alleles (represented by the iTEM
score) result, in fact, in less effective modulation of T cell reactivity. This was well exemplified in the experiments showing only
partial suppression of CTL activity with hTreg289 and complete
suppression with hTreg167 due to differences in binding affinity
to the donor’s MHC II alleles; correlation between the iTEM score
and hTreg167-mediated suppression of CTLs is also suggestive of
such correlation. However, the affinity of Tregitopes for several
MHC II alleles20 and the coexpression of strings composed of
Tregitopes that bind to multiple HLA could allow administration
of the same tolerizing vector to most subjects.
An important implication of the study presented here is that
our strategy could be potentially applied to a variety of diseases.
AAV vectors per se are among the most efficient vectors for in vivo
gene transfer,1 they have been administered both systemically and
locally to humans with an excellent safety profile, and they have
been shown to promote tolerance rather than immunity against
the expressed transgenes.45 The availability of a wide range of AAV
capsid serotypes with different tissue tropism,44 the possibility to
further direct tropism of AAV vectors to a determined tissue,48
and the broad range of tissue-specific and/or inducible promoters available constitute a great advantage of the strategy presented
here over the systemic administration of peptides or immunosuppressive drugs.
In conclusion, the work presented here shows that MHC II
epitopes derived from IgG can be used as tolerizing agents to
modulate CD8+ T cell responses in vitro and in vivo. The use of
AAV vectors as delivery vehicles for Tregitopes represents a novel
strategy to deliver tolerogenic peptides to modulate immune
responses to viral vectors and other antigens.
www.moleculartherapy.org vol. 21 no. 9 sep. 2013
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MATERIALS AND METHODS

Peptides. The AAV2 MHC I epitopes VPQYGYLTL and SADNNNSEY,

restricted to the human HLA-B*0702 and HLA-A*0101 alleles, respectively,4 were obtained from Genemed Synthesis. The AAV2 MHC I
epitope SNYNKSVNV, restricted to the mouse allele Kb,26 was also
obtained from Genemed Synthesis; this epitope from the AAV2 capsid is not conserved in the AAV1 capsid. The HLA-B*0702-restricted
peptide epitopes from EBV (RPPIFIRRL), CMV (TPRVTGGGAM),
HCV (DPRRRSRNL), and influenza (QPEWFRNVL) were obtained
from Proimmune. hTreg-167 (PAVLQSSGLYSLSSVVTVPSSSLGTQ),
hTreg-289 (EEQYNSTYRVVSVLTVLHQDW), the scamble negative
control peptides Scramble 1 (SPYQSVTSSVLGLLSPVSASVSQTLG),
Scramble 2 (SSGVQPLLVVYSSLVTSPSASSGLTQ), and Scramble 3
(SSGSQALVLVYSPSSVLVPTSSTGQL), and the control peptide from
influenza hemagglutinin (307-319) (PKYVKQNTLKLAT) were synthesized by 21st Century Biochemicals with a 5′ acylation modification and
an amidylation modification at the 3′ terminus. All peptides were resuspended to a concentration of 5 mg/ml. Affinity of the Tregitopes used in
this study for human class II alleles has been previously discussed.20
Vectors. The AAV serotype 1 vectors used in the study encoded the AAV2
VP1 capsid protein fused to the Tregitope sequence (AAV-Tregitope) or a
scrambled version of the Tregitope sequence (AAV-Scramble). A PACE/furin
cleavage sequence was inserted between the VP1 sequence and the Tregitope/
Scramble sequence to ensure cleavage of the two proteins.27 Expression of
transgenes was driven by a CMV promoter/enhancer sequence. All AAV
vectors were administered at a dose of 2 × 1011 vector genomes (vg)/mouse.
The adenoviral vector expressing the AAV2 VP1 capsid protein (Ad-AAV2)
was previously described.26 The Ad-AAV2 vector was given at a dose of
1 × 1011 virus particles (vp)/mouse. All vectors were produced as previously
described26 and injected intramuscularly (intramuscularly).
Cell lines, peripheral blood mononuclear cells. The human hepatocyte cell

line HHL5 (carrying the human HLA-A*0101 allele) and the HHL5 cell line
genetically modified to express the human HLA-B*0702 allele, used as targets in the CTL assay, were previously described.7,8 Healthy donor PBMCs
were obtained from Cellular Technologies (Cleveland, OH) and selected
based on their HLA haplotype; so, they were carrier of the HLA-A*0101 or
HLA-B*0702 alleles as well as matching the DRB1 alleles previously reported
to be high-affinity binders of Tregitopes used in the study.20 All human
specimens were deidentified and handled under a protocol approved by the
Children’s Hospital of Philadelphia’s Institutional Review Board.
In vitro expansion of T cells. Restimulation of PBMCs in vitro was performed as previously described.4 Briefly, cells were thawed, washed,
counted, and resuspended at a concentration of 2 × 106 cells/ml in AIM-V
lymphocyte media (Invitrogen Gibco, Carlsbad, CA) containing 3%
human serum (Bioreclamation), 1% L-glutamine (Invitrogen Gibco), and
1% penicillin/streptomycin (Invitrogen Gibco). For each expansion condition, 1 × 106 cells were added to a well in a 24-well plate (BD Falcon).
1 × 106 of autologous-irradiated PBMC (3000 rad) were also added to each
well together with 10 ng/ml of human recombinant IL-7 (R&D Systems,
Minneapolis, MN). According to the experimental conditions for each
expansion well, peptides were added at a final concentration of 10 µg/ml
in 5% CO2, 10 ng/well of human IL-2 (Roche, Indianapolis, IN) was added
to the cell culture and replenished every 48 hours thereafter. Cells were
divided into new wells as the expansion proceeded, and antigenic stimulation (antigen and feeder cells) was repeated every 7–10 days for up to two
rounds of restimulation. Expanded CD8+ T cells were characterized after
each round of stimulation by IFN-γ ELISpot, MHC I pentamer staining, or
intracellular cytokine staining.
Flow cytometry, intracellular cytokine staining, and polyfunctional analysis of T cell activation markers. Surface staining and IFN-γ intracellular

cytokine staining was performed as previously described.4,26 Regulatory T
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cell staining was performed using human or mouse regulatory Treg-staining
kits (eBioscience, San Diego, CA) containing antibodies for CD4, CD25,
and FoxP3. For polyfunctional analysis of T cell activation markers, cells
were washed and counted using an automated cell counter (Invitrogen),
resuspended at a concentration of 2 × 106 cells/ml, and incubated overnight
at 37 °C in 5% CO2. The next day, 1 × 106 cells were treated with 1 µg each
of anti-CD28 and anti-CD49d antibodies (BD Biosciences, Franklin Lakes,
NJ), and with 10 µl of anti-CD107a antibody (BD Biosciences). Cells were
then stimulated with 10 µg/ml of peptide, 10 µg/ml of Staphylococcal enterotoxin B (SEB, Sigma, St Louis, MO), or left untreated as a negative control
for 1 hour at 37 °C, 5% CO2 prior to adding 10 µg of brefeldin A (Sigma) and
0.7 µl of monensin (GolgiStop, BD Biosciences). After an additional 5-hour
incubation, cells were washed in PBS and stained for the surface markers
CD3, CD4, CD8, CD14, CD16, and CD19 (BD Biosciences or Caltag). Cells
were then washed once with PBS 2% FBS, and then fixed and permeabilized
with 200 µl of Cytofix/Cytoperm solution (BD Biosciences). Intracellular
staining for cytokines was performed at room temperature using antibodies against IFN-γ, TNF-α, and IL-2 (BD Biosciences). Cells were fixed with
2% paraformaldehyde prior to acquisition on a FACS Canto II flow cytometer; analysis was conducted using FACSDiva (BD Biosciences) and Flowjo
(Treestar) software.
CTL assay. The CTL assay was performed as previously described.7,8 Briefly,

lactate dehydrogenase (LDH) release following CTL-mediated target lysis
was measured with the CytoTox 96 Non Radioactive Cytotoxicity Assay
(Promega, Madison, WI). Five thousand HHL5 target cells were plated in
each well of a Microtest Primaria flat-bottom 96-well plate (BD Falcon) in
DMEM containing no serum. Targets were either transduced at a range of
multiplicity of infections (see Results) with an AAV vector, or loaded with
MHC class I epitopes at indicated concentrations (see Results) and incubated for 18 hours at 37 °C, 5% CO2. Teff cells were added at a Teff:target
ratio of 10:1 unless otherwise noted, and cell lysis was measured after four
hours of incubation.
Cytokine profiling. Conditioned medium was sampled immediately

after cells were plated (day 0) and then twice daily on day 4, 8, 13, and 18
during in vitro restimulation and prior to feeding cells with IL-2. Media
withdrawn for sampling was replaced with an equal volume of medium.
Cytokine analysis was performed by ELISA. The multiplex assay was performed using a Milliplex MAP Human Cytokine/Chemokine Pre-mixed
14-plex kit (Millipore, Billercia, MA) on a Luminex 200 instrument and
analyzed with xPONENT software (Luminex, Austin, TX). Analytes and
individual lower limit of detection were as follows: granular-macrophage
colony stimulating factor (GM-CSF): 2.75 pg/ml; IFN-γ: 2.97 pg/ml; IL-1
β: 1.64 pg/ml; IL-2: 2.51 pg/ml; IL-4: 2.94 pg/ml; IL-5: 3.05 pg/ml; IL-6:
3.01 pg/ml; IL-7: 2.95 pg/ml; IL-8: 3.01 pg/ml; IL-10: 0.41 pg/ml; IL-12
(p70): 2.99 pg/ml; IL-13: 1.31 pg/ml; monocyte chemotactic protein 1
(MCP-1): 2.97 pg/ml; and TNF-α: 3.01 pg/ml. The multiplex assay did not
show variation in any of the cytokines or chemokines tested (not shown).

Isolation and depletion of T cell subsets. For studies involving the selec-

tion or depletion of subpopulations of T cells, antibody-coated magnetic
bead separation was performed to negatively select for untouched CD4+
and CD8+ T cells, or to deplete CD25+, CD4+, or CD8+ T cell populations
(Invitrogen Dynal) according to the manufacturer’s protocols. Isolated
cell populations were either used directly in CTL assays or cultured until
assayed. Surface staining followed by flow cytometry was used to confirm
the success of cell separation or depletion.

Assay for contact-dependent inhibition of cytotoxicity. PBMCs were sep-

arated into CD4-depleted and CD8-depleted fractions and then cultured
in separate chambers of a 0.4 µM Transwell permeable support (Corning).
Cells were restimulated for 2 weeks in the presence of the AAV MHC I
peptide VPQYGYLTL and hTreg167 as described above. After restimulation, cells were harvested from the CD4-depleted chamber of the transwell
(containing the CD8+ fraction of PBMCs) and tested in a CTL assay.
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MHC I blockade experiment. To demonstrate that antigen specificity of Tregitope-mediated CTL suppression is dependent on MHC I, we
performed a MHC I blockade. We previously described the development of soluble TCR monomers specific for the HLA-B*0702 epitope
VPQYGYLTL.4 This TCR is HLA- and epitope-specific and can mediate
complete blockage of MHC I.8 In this experiment, PBMCs from the same
donor were restimulated in vitro with AAV+hTreg167, AAV, or hTreg167.
Cells stimulated with AAV+hTreg167 were used to negatively select
CD4+ T cells using Dynabeads (Invitrogen Dynal). These cells were
then incubated with 0, 1, 5, or 20 µg/ml of soluble TCR monomers at
room temperature in PBS with 1% BSA. After washing twice in DMEM
(Gibco, Carlsbad, CA), cells were mixed 1:1 with Teff derived from AAVrestimulated PBMCs and used in a CTL assay.
As a control, Teff derived from AAV-restimulated PBMCs (in the
absence of Tregitope) were used (Figure 5C, AAV only).
One additional control consisted of CD4+ T cells derived from
PBMCs restimulated with hTreg167 only mixed at a 1:1 ratio with Teff
derived from PBMC restimulated with AAV antigen only (Figure 5C,
hTreg167 only). In this control, suppressor cells were never exposed to the
MHC I epitope from AAV.
Finally, a third control consisted in the addition of soluble TCR
monomers to the CTL assay in which effector cells were restimulated with
AAV peptide only.
Animal studies. All mouse experiments were repeated at least twice,
conducted using 8- to 10-week-old male C57BL/6 mice (Charles River
Laboratories, Wilmington, MA), and were approved by the Children’s
Hospital of Philadelphia Institutional Animal Care and Use Committee.
Animals received the vectors intramuscularly via direct injection into
both hind limbs. Blood samples were collected into heparinized capillary
tubes (Fisher Scientific, Waltham, MA) for antibody analysis as previously
described;45 spleens and lymph nodes were collected and briefly stored in
cold medium until processed for lymphocyte isolation. Muscle samples
were snap-frozen in liquid nitrogen for RNA extraction. For cell extraction, muscle samples were collected in cold Hank’s balanced salt solution
(HBSS, Invitrogen Gibco) containing 0.05% of proteinase K (Pronase,
Invitrogen Gibco), homogenized on a gentleMACS Dissociator (Miltenyi
Biotec, Bergisch Gladbach, Germany), digested for 1 hour at 37 °C, then
further homogenized, filtered through a 70 µm cell strainer, and washed
twice in RPMI 1640 medium (Invitrogen Gibco).
Quantitative real-time PCR for transgene expression and vector gene copy number. RNA was extracted from snap-frozen mus-

cle using TRIzol/chloroform and additional purification performed
with RNEasy columns (QIAGEN). cDNAs were generated using the
High-Capacity cDNA Reverse Transcription Kit with RNase Inhibitor
(Applied Biosystems, Foster City, CA). Taqman Universal Master
Mix II (Applied Biosystems) was used for quantitative real-time PCR.
PrimeTime Standard qPCR Assays were ordered from Integrated
DNA Technologies. For AAV2 VP1 detection, the following reagents
were used: forward primer: 5′-GACATTTTCACCCCTCTCCC-3′;
reverse primer: 5′-CAAACTTTGCCGCACTGAAG-3′; and probe
sequence: 5′-/56-FAM/ACACCCTCC/ZEN/TCCACAGATTCTCATCA/
3IABkFQ/-3′. GAPDH was used as an internal control: forward primer:
5′-AATGGTGAAGGTCGGTGTG-3′; reverse primer: 5′-GTGGAGTCA
TACTGGAACATGTAG-3′; and probe 5′-/56-FAM/TGCAAATGG/ZEN/
CAGCCCTGGTG/3IABkFQ/-3′. The same set of primers and probe
were used to determine vector genome copy number on genomic DNA
extracted from injected muscle. The assays were run on a Mastercycler
Realplex2 (Eppendorf, Hauppauge, NY).
Bioinformatics and statistical analysis. Tregitope-binding scores (iTEM)

were obtained from EpiVax (EpiVax, Providence, RI) using the EpiMatrix
and ClustiMer epitope-mapping algorithms as previously described.20,25,49
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Unpaired t-test was used to compare means across experimental groups,
two-way ANOVA was used to compare levels of cytokines secreted in
PBMC cultures. Linear regression was used to analyze the relationship
between iTEM score and inhibition of CTL activity. Statistical analysis was
performed using GraphPad (GraphPad Software, La Jolla, CA); P values
<0.05 were considered significant.

SUPPLEMENTARY MATERIAL
Figure S1. Defining an experimental design for the in vitro testing of
Tregitopes efficacy.
Figure S2. The binding score of Tregitopes for MHC II shows a rough
correlation with the inhibition of CTL activity
Figure S3. Both CD4+ and CD8+ T cells proliferate in vitro in the
presence of Tregitopes.
Figure S4. In vitro restimulation of PBMCs with Tregitopes leads to
an antiinflammatory cytokine response in the tissue culture media.
Figure S5. Expression of Tregitopes in vivo is associated with reduced
T cell infltrates in muscle and lower anti-AAV antibody titers.
Figure S6. After AAV vector delivery in vivo, transgene expression
and vector genome copy number can be detected in injected muscle.
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